Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, MultiCenter Study of the Efficacy and Safety of MPC-SHRC for the Relief of Symptoms Associated With Uncomplicated Urinary Tract Infections
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs MPC SHRC (Primary)
- Indications Urinary tract infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Mission Pharmacal
- 03 May 2017 New trial record